
Explore ARM Holdings PLC's Q3 2025 financial report filed on November 5, detailing key performance metrics from July 1 to September 30, in compliance with SEC regulations.

Explore ARM Holdings PLC's Q3 2025 financial report filed on November 5, detailing key performance metrics from July 1 to September 30, in compliance with SEC regulations.

Explore PDD Holdings Inc.'s Form 6-K for August 2025, detailing financial insights, key exhibits, and executive updates from Chairman Lei Chen.

Explore AstraZeneca PLC's August 2025 Form 6-K report detailing The Capital Group's voting rights changes, impacting governance. Key insights on acquisitions and shareholder dynamics.

Explore Arm Holdings PLC's Form 6-K report detailing significant updates for August 11, 2025. Key insights on financials and events impacting Q2 2026.

Explore GLOBALFOUNDRIES Inc.'s Form 6-K filing for August 2025, featuring key financial updates, signed by CFO John Hollister, and an attached press release for detailed insights.

Explore ARM Holdings PLC's Form 6-K for Q2 2025, detailing significant financial updates in XBRL format. Stay informed about their latest reporting period and performance insights.

Explore the June 2025 Form 6-K report for GLOBALFOUNDRIES Inc., detailing governance, annual meeting, and SEC compliance.

Explore ARM Holdings PLC's 6-K report detailing significant Q1 2025 events. Key insights for investors on performance and future implications.

On February 24, 2025, Telix Pharmaceuticals Limited filed a Form 6-K announcing the change of its reporting currency to USD. Insights on market impact and compliance included.

Antelope Enterprise Holdings Ltd. amends Form 6-K to clarify auditor changes and correct filing date. Key updates on ARK PRO CPA dismissal and AssentSure PAC engagement.

Explore Galapagos NV's February 2025 Form 6-K, detailing financial filings, recent press releases, and compliance with SEC regulations.

Explore Agora, Inc.'s February 2025 Form 6-K report highlighting CFO Jingbo Wang's insights, filing details, and important exhibits.